




Instance: composition-en-6ad927719fc570edf8a72cacebe37a51
InstanceOf: CompositionUvEpi
Title: "Composition for prehevbri Package Leaflet"
Description:  "Composition for prehevbri Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1641/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6ad927719fc570edf8a72cacebe37a51)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - prehevbri"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What PreHevbri is and what it is used for  </li>
<li>What you need to know before you receive  PreHevbri </li>
<li>How PreHevbri is given </li>
<li>Possible side effects  </li>
<li>How to store PreHevbri </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What prehevbri is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What prehevbri is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PreHevbri is a vaccine which prevents infection caused by the hepatitis B virus. It is used in adults to 
protect from all known types of hepatitis B virus.  </p>
<p>PreHevbri may also protect against hepatitis D which can only occur in people who have hepatitis B 
infection. </p>
<p>What is hepatitis B 
- Hepatitis B is an infectious illness of the liver caused by a virus. Hepatitis B virus infection can 
cause serious liver problems such as  cirrhosis  (scarring in the liver) or liver cancer. 
- Some people infected with the hepatitis B virus become carriers, which means that they may not 
feel ill but continue to have the virus in their body and they can still infect other people. 
- The disease spreads by the hepatitis B virus entering the body through contact with an infected 
person s body fluids, such as in the vagina, blood, semen, or spit (saliva). A mother who is a 
carrier of the virus can also pass the virus to her baby at birth. 
- The main signs of the illness include mild signs of flu (such as headache and fever, feeling 
very tired, dark urine, pale stools [faeces], and yellowing of the skin and eyes [jaundice]). 
However, some people with hepatitis B do not look or feel ill. </p>
<p>How PreHevbri works </p>
<p>When a person is given the PreHevbri vaccine, it helps the body s natural defence system 
(immune system) produce specific protection (antibodies) against the hepatitis B virus. </p>
<ul>
<li>PreHevbri contains a substance (called an  adsorbent )  which improves the body s production 
of antibodies and makes the protection last for longer. </li>
<li>A course of three injections of PreHevbri is required to provide full protection against 
hepatitis B. </li>
<li>PreHevbri is not used to treat a person who is already infected with the hepatitis B virus 
including anyone who has previously been infected and who is now a carrier of the virus. </li>
<li>Prehevbri is a  3-antigenic  vaccine, which contains small amounts of the three antigens 
(pre-S1, pre-S2, S) from the  outer coating  of the hepatitis B virus. This  outer coating  is not 
infectious and cannot make you ill. </li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take prehevbri"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take prehevbri"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You must NOT receive PreHevbri:</p>
<ul>
<li>if you are allergic to the active substance or any of the other ingredients of this vaccine <br />
(listed in section 6). Signs of an allergic reaction may include breathing difficulty, swelling, 
light-headedness, fast heartbeat, sweating, and loss of consciousness. </li>
<li>if you have ever previously had a sudden, life-threatening allergic reaction to any vaccine 
against hepatitis B.  </li>
</ul>
<p>You must not receive PreHevbri if either of the above apply to you. If you are not sure, talk to your 
doctor, pharmacist or nurse before receiving PreHevbri. </p>
<p>Warnings and precautions<br />
- Your doctor, pharmacist or nurse will make sure that appropriate medical treatment is readily 
available in case you should develop a sudden and rare anaphylactic reaction (a very severe 
allergic reaction with symptoms such as breathing difficulty, swelling, light-headedness, fast 
heartbeat, sweating, and loss of consciousness) after you have been given the vaccine. This 
reaction may occur when any vaccine is injected, including PreHevbri. Seek urgent medical 
attention if you develop any of these symptoms after you are given the injectionas this could be 
a life-threatening allergic reaction.<br />
- Fainting can occur following, or even before, any needle injection, therefore tell the doctor, 
pharmacist or nurse if you fainted with a previous injection. 
- If you are ill with a high fever, tell your doctor, pharmacist or nurse as they may delay the 
vaccination until you are feeling better. A minor infection such as a cold should not be a 
problem, but your doctor, pharmacist or nurse will decide if you could still be vaccinated. 
- If you have low blood platelets or any blood-clotting disorders, then bleeding or bruising may 
occur after you are given the injection. Tell your doctor, pharmacist or nurse if you have any of 
these conditions.<br />
- PreHevbri may not prevent hepatitis B infection if you already have an unrecognised hepatitis B 
infection at the time of vaccine administration. 
- As with any vaccine, PreHevbri may not protect all people who are vaccinated. 
- PreHevbri does not protect you against other liver infections such as hepatitis A, C, and E. 
- If you are on dialysis for a kidney problem or if you have a weakened immune system your 
doctor may need to do a blood test to check if the vaccination has worked well enough to 
protect you against hepatitis B.  </p>
<p>If you have any concerns or you are not sure about any of the above, talk to your doctor, pharmacist or 
nurse before receiving PreHevbri.  </p>
<p>Children and adolescents 
PreHevbri has not been fully tested in children under 18 years of age, it should not be used in this age 
group.  </p>
<p>Other medicines and PreHevbri 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other 
medicines, including any other vaccine.  </p>
<p>In addition to PreHevbri, you may be given an injection of hepatitis B 'immuno-globulins'. This will 
give you immediate short-term protection against hepatitis B infection. If this happens your doctor, 
pharmacist or nurse will make sure that the two injections are given in different parts of the body. </p>
<p>Pregnancy and breast-feeding<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, 
ask your doctor, pharmacist or nurse for advice before being given this vaccine. </p>
<p>It is unknown whether PreHevbri is excreted in human milk. A risk to the suckling child cannot be 
excluded. Discuss with your doctor or nurse whether the risks and benefits of breast-feeding your child 
outweigh the benefit of vaccination and whether you should stop breast-feeding. </p>
<p>Driving and using machines 
PreHevbri is unlikely to have any effect on the ability to drive and use machines. If you feel tired, 
or have a headache or feel dizzy after having the vaccine, do not drive or use any machines until you 
feel well again.  </p>
<p>PreHevbri contain sodium and potassium 
This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. that is to say is essentially 
'sodium-free . </p>
<p>This vaccine  contains less than 1 mmol potassium (39 mg) per dose, i.e. that is to say is essentially 
 potassium-free . </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take prehevbri"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take prehevbri"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PreHevbri will be given to you as an injection by a doctor, pharmacist or nurse. The vaccine will 
usually be injected into a muscle in your upper arm. </p>
<p>You will be given a total of three injections. Each injection will be given on separate visits:</p>
<ul>
<li>1st injection: on a date agreed with your doctor, pharmacist or nurse;  </li>
<li>2nd injection: 1 month after the 1st injection; </li>
<li>3rd injection: 6 months after the 1st injection. </li>
</ul>
<p>The recommended dose for each injection is 10 micrograms (1 mL of suspension for injection ). </p>
<p>If you forget a scheduled dose of PreHevbri 
If you miss a scheduled dose, talk to your doctor, pharmacist or nurse to arrange another visit to 
receive the missed dose. </p>
<p>Make sure you receive the complete course of three injections or you may not be fully protected.  </p>
<p>If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them. </p>
<p>Very common (may affect more than 1 in 10 people):</p>
<ul>
<li>feeling very tired; </li>
<li>pain or tenderness at the injection site; </li>
<li>itching at the injection site; </li>
<li>muscle pain; </li>
<li>headache.  </li>
</ul>
<p>Common (may affect up to 1 in 10 people):</p>
<ul>
<li>diarrhoea; </li>
<li>feeling or being sick;  </li>
<li>stomach pain; </li>
<li>redness, bruising or swelling at the injection site; </li>
<li>rash; </li>
<li>dizziness; </li>
<li>joint pain;  </li>
<li>fever. </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people):</p>
<ul>
<li>swollen lymph nodes; </li>
<li>hives or itchy skin;  </li>
<li>flushing or hot flushes. </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this vaccine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store prehevbri"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store prehevbri"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. </p>
<p>Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date 
refers to the last day of that month. </p>
<p>Store vials in a refrigerator (2 C to 8 C). Store in the original package in order to protect from light. 
Do not freeze.  </p>
<p>Do not throw away any vaccines via wastewater. Any unused medicinal product or waste material 
should be disposed of in accordance with local requirements. These measures will help protect the 
environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What PreHevbri contains  </p>
<p>One dose (1 mL) contains:</p>
<ul>
<li>Active substances: 10 micrograms of hepatitis B surface antigens (S [83%], pre-S2 [11%] and 
pre-S1 [6%]) 1, 2  </li>
</ul>
<p>1 Adsorbed on 500 micrograms of Al3+ as aluminium hydroxide, hydrated </p>
<p>2 Produced in Chinese Hamster Ovary cells by recombinant DNA technology </p>
<ul>
<li>The other ingredients are sodium chloride, potassium chloride, disodium phosphate 
dodecahydrate, potassium dihydrogen phosphate, sodium hydroxide (for pH adjustment), 
hydrochloric acid (for pH adjustment), water for injections. </li>
</ul>
<p>What PreHevbri looks like and contents of the pack 
PreHevbri is a clear, colourless suspension with a fine white deposit. When the vial is shaken the 
suspension forms a slightly white opaque suspension. </p>
<p>PreHevbri is supplied in vials containing 1 mL. Each vial is for single use only. </p>
<p>Packs of 1 or 10 single-dose vials are available. </p>
<p>Not all pack sizes may be marketed.  </p>
<p>Marketing Authorisation Holder<br />
VBI Vaccines B.V. 
Delflandlaan 1<br />
Queen s Tower, No. 1062EA Amsterdam 
Netherlands </p>
<p>Manufacturer 
MIAS Pharma Limited 
Suite 1, First Floor, Stafford House 
Strand Road 
Portmarnock, D13 WCIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:  </p>
<p>Belgi /Belgique/Belgien 
Valneva France SAS 
France 
T l/Tel: +43 120620 1e-mail: medinfo@valneva.com  </p>
<p>Lietuva 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>VBI Vaccines B.V. 
Netherlands 
Te .: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Luxembourg/Luxemburg 
VBI Vaccines B.V. 
Netherlands 
T l/Tel: +31 20 2997e-mail: medinfo@vbivaccines.com<br />
 esk  republika 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com  </p>
<p>Magyarorsz g 
VBI Vaccines B.V. 
Netherlands 
Tel.: +31 20 2997e-mail: medinfo@vbivaccines.com 
Danmark 
Valneva Sweden AB 
Sweden 
Tlf: +43 120620 1e-mail: medinfo@valneva.com  </p>
<p>Malta 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Deutschland 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Nederland 
Valneva France SAS 
France 
Tel: +43 120620 1e-mail: medinfo@valneva.com 
Eesti 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Norge 
Valneva Sweden AB 
Sweden 
Tlf: +43 120620 1e-mail: medinfo@valneva.com </p>
<p>VBI Vaccines B.V. 
Netherlands 
 : +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>sterreich 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Espa a 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Polska 
VBI Vaccines B.V. 
Netherlands 
Tel.: +31 20 2997e-mail: medinfo@vbivaccines.com 
France 
VBI Vaccines B.V. 
Netherlands 
T l: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Portugal 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Hrvatska 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Rom nia 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Ireland 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Slovenija 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
 sland 
VBI Vaccines B.V. 
Netherlands 
S mi: +31 20 2997Netfang: medinfo@vbivaccines.com </p>
<p>Slovensk  republika 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com<br />
Italia 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Suomi/Finland 
Valneva Sweden AB 
Sweden 
Puh/Tel: +43 120620 1e-mail: medinfo@valneva.com  </p>
<p>VBI Vaccines B.V. 
Netherlands 
 : +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Sverige 
Valneva Sweden AB 
Tel: +43 120620 1e-mail: medinfo@valneva.com 
Latvija 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
United Kingdom (Northern Ireland) 
Valneva Austria GmbH 
Austria 
Tel: +43 120620 1e-mail: medinfo@valneva.com  </p>
<p>This leaflet was last revised in MM/YYYY. </p>
<p>Other sources of information </p>
<p>Detailed information on this vaccine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. </p>
<hr />
<p>The following information is intended for healthcare professionals only: </p>
<p>Storage 
- Vials should be stored in a refrigerator (2 C to 8 C) ).Store in the original carton in order to 
protect from light.<br />
- Do not freeze .  </p>
<p>Preparation 
- The vaccine should be used under aseptic conditions. 
- The suspension is slightly white opaque when mixed. Upon settling, the solution is clear and 
colourless with a white deposit. 
- The suspension should be visually inspected prior to administration. In the event of any foreign 
particulate matter and/or variation of physical aspect being observed, discard the vaccine.<br />
- The vial should be shaken well prior to administration. </p>
<p>Administration 
- PreHevbri should be injected intramuscularly into the deltoid muscle.<br />
- Do not inject PreHevbri into the gluteal muscle, or intradermally or intravascularly.<br />
- Each vial is for single use only. 
- PreHevbri must not be mixed with other medicinal products. </p>
<p>Disposal 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. </p> </div>"""      



Instance: composition-da-6ad927719fc570edf8a72cacebe37a51
InstanceOf: CompositionUvEpi
Title: "Composition for prehevbri Package Leaflet"
Description:  "Composition for prehevbri Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1641/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6ad927719fc570edf8a72cacebe37a51)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - prehevbri"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du får PreHevbri 
3. Sådan gives PreHevbri 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PreHevbri er en vaccine, der forebygger infektion forårsaget af hepatitis B-virus. Den anvendes hos 
voksne til at beskytte mod alle kendte typer hepatitis B-virus. </p>
<p>PreHevbri kan også beskytte mod hepatitis D, der kun kan forekomme hos personer, der er smittet 
med hepatitis B. </p>
<p>Hvad er hepatitis B? 
- Hepatitis B er en smitsom leversygdom, der skyldes et virus. Hepatitis B-virusinfektion kan 
medføre alvorlige leverproblemer som f.eks. cirrose (ardannelse i leveren) eller leverkræft. 
- Nogle personer, der er smittet med hepatitis B-virusset, bliver bærere. Det vil sige, at de måske 
ikke føler sig syge, men at de fortsat har virusset i kroppen og derfor stadigvæk kan smitte 
andre. 
- Sygdommen spredes ved, at smitten kommer ind i kroppen gennem kontakt med en smittet 
persons kropsvæsker, f.eks. i skeden, blod, sæd eller spyt. En moder, der er bærer af virusset, 
kan også give det videre til sit barn ved fødslen. 
- De primære tegn på sygdommen er bl.a. milde influenzasymptomer (f.eks. hovedpine og feber, 
voldsom træthed, mørkfarvet urin, bleg afføring [fæces], og gulfarvning af hud og øjne 
[gulsot]). Det er dog ikke alle, der er smittet med hepatitis B, som ser syge ud eller føler sig 
syge. </p>
<p>Sådan virker PreHevbri </p>
<p>Når en person vaccineres med PreHevbri, hjælper det kroppens naturlige forsvar 
(immunforsvaret) med at producere specifik beskyttelse (antistoffer) mod hepatitis B-virusset. </p>
<ul>
<li>PreHevbri indeholder et stof (en såkaldt "adsorbent"), der forbedrer kroppens produktion af 
antistoffer og bevirker, at beskyttelsen holder længere. </li>
<li>En serie på tre injektioner af PreHevbri er nødvendig for at give fuld beskyttelse mod 
hepatitis B. </li>
<li>PreHevbri anvendes ikke til behandling af en person, der allerede er smittet med hepatitis 
B-virus, herunder enhver, som tidligere er smittet, og som nu er bærer af virusset. </li>
<li>PreHevbri er en "3-antigen"-vaccine, der indeholder små mængder af de tre antigener (pre S1, 
pre S2, S) fra hepatitis B-virussets "ydre lag". Dette "ydre lag" er ikke smitsomt og kan ikke 
gøre dig syg. </li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  prehevbri"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  prehevbri"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må IKKE få PreHevbri:</p>
<ul>
<li>hvis du er allergisk over for det aktive stof eller et af de øvrige indholdsstoffer i denne vaccine 
(anført i punkt 6). Tegn på en allergisk reaktion kan være vejrtrækningsbesvær, hævelse, 
svimmelhed, hurtig hjerterytme, svedtendens og bevidsthedstab. </li>
<li>hvis du nogensinde har haft en pludselig, livstruende allergisk reaktion over for en vaccine mod 
hepatitis B. </li>
</ul>
<p>Du må ikke få PreHevbri, hvis nogen af ovenstående punkter gælder for dig. Er du i tvivl, så spørg 
lægen, apotekspersonalet eller sygeplejersken, før du får PreHevbri. </p>
<p>Advarsler og forsigtighedsregler 
- Lægen, apotekspersonalet eller sygeplejersken vil sørge for, at der er umiddelbar adgang til 
passende medicinsk behandling, hvis du får en pludselig og sjælden anafylaktisk reaktion (en 
meget alvorlig allergisk reaktion med symptomer som f.eks. vejrtrækningsbesvær, hævelse, 
svimmelhed, hurtig hjerterytme, svedtendens og bevidsthedstab) efter at have fået vaccinen. 
Denne reaktion kan forekomme, når en vaccine injiceres, herunder PreHevbri. Søg akut 
lægehjælp, hvis du udvikler nogen af disse symptomer, efter at du har fået injektionen, da det 
kan være en livstruende allergisk reaktion. 
- Besvimelse kan forekomme efter eller endog før en injektion. Derfor skal du informere lægen, 
apotekspersonalet eller sygeplejersken, hvis du tidligere er besvimet i forbindelse med en 
injektion. 
- Hvis du er syg og har høj feber, så fortæl det til lægen, apotekspersonalet eller sygeplejersken, 
da de kan udsætte vaccinationen, indtil du har det bedre. En mindre infektion, f.eks. forkølelse, 
bør ikke være et problem, men lægen, apotekspersonalet eller sygeplejersken vil beslutte, om du 
stadig kan vaccineres. 
- Hvis du har et lavt antal blodplader eller andre blodpropsygdomme, kan der opstå blødning eller 
blå mærker, efter at du har fået injektionen. Informer lægen, apotekspersonalet eller 
sygeplejersken, hvis du har nogen af disse sygdomme. 
- PreHevbri forebygger muligvis ikke hepatitis B-infektion, hvis du allerede har en 
ikkekonstateret hepatitis B-infektion på tidspunktet for administration af vaccinen. 
- Ligesom med andre vacciner beskytter PreHevbri måske ikke alle personer, der vaccineres. 
- PreHevbri beskytter dig ikke mod andre leverinfektioner såsom hepatitis A, C og E. 
- Hvis du er i dialyse pga. et nyreproblem, eller hvis dit immunsystem er svækket, kan lægen 
være nødt til at tage en blodprøve for at tjekke, om vaccinationen har virket godt nok til at 
beskytte dig mod hepatitis B. </p>
<p>Hvis du har betænkeligheder eller i tvivl om noget af ovenstående, kan du tale med lægen, 
apotekspersonalet eller sygeplejersken, før du får PreHevbri. </p>
<p>Børn og unge 
PreHevbri er ikke fuldt undersøgt hos børn under 18 år, og bør ikke anvendes i denne aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med PreHevbri 
Informer altid lægen, apotekspersonalet eller sygeplejersken, hvis du tager andre lægemidler, for nylig 
har taget andre lægemidler eller planlægger at tage andre lægemidler. Dette gælder også andre 
vacciner. </p>
<p>Ud over PreHevbri kan du få en injektion af hepatitis B-immunglobuliner. Dette vil give dig 
øjeblikkelig beskyttelse mod hepatitis B-infektion på kort sigt. Hvis dette sker, vil lægen, 
apotekspersonalet eller sygeplejersken sørge for, at de to injektioner gives i forskellige dele af 
kroppen. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge lægen, apotekspersonalet eller sygeplejersken til råds, før du får denne vaccine. </p>
<p>Det er ukendt, om PreHevbri udskilles i modermælken. En risiko for det ammede barn kan ikke 
udelukkes. Tal med lægen eller sygeplejersken om, hvorvidt risici og fordele ved amning af dit barn 
opvejer fordelene ved vaccination, og om du bør holde op med at amme. </p>
<p>Trafik- og arbejdssikkerhed 
PreHevbri forventes ikke at påvirke evnen til at køre og betjene maskiner. Hvis du føler dig træt eller 
har hovedpine eller føler dig svimmel efter at du har fået vaccinen, må du ikke føre motorkøretøjer og 
betjene maskiner, før du får det godt igen. </p>
<p>PreHevbri indeholder natrium og kalium 
Denne vaccine indeholder mindre end 1 mmol natrium (23 mg) pr. dosis, dvs. er i det væsentlige 
"natriumfri". </p>
<p>Denne vaccine indeholder mindre end 1 mmol kalium (39 mg) pr. dosis, dvs. er i det væsentlige 
"kaliumfri". </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage prehevbri"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage prehevbri"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PreHevbri vil blive givet som en injektion af en læge eller sygeplejerske eller på apoteket. Vaccinen 
vil normalt blive injiceret i en muskel i overarmen. </p>
<p>Du vil få i alt tre injektioner. Hver injektion vil blive givet ved separate besøg:</p>
<ul>
<li>Første injektion: på en dato, der er aftalt med lægen, apotekspersonalet eller sygeplejersken. </li>
<li>Anden injektion: 1 måned efter den første injektion. </li>
<li>Tredje injektion: 6 måneder efter den første injektion. </li>
</ul>
<p>Den anbefalede dosis ved hver injektion er 10 mikrogram (1 ml injektionsvæske, suspension). </p>
<p>Hvis du har glemt en planlagt dosis PreHevbri 
Hvis du har glemt en planlagt dosis, skal tale med lægen, apotekspersonalet eller sygeplejersken om at 
få den glemte dosis. </p>
<p>Vær sikker på, at du får alle tre injektioner, ellers er du måske ikke er fuldt beskyttet. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre vacciner give bivirkninger, men ikke alle får dem. </p>
<p>Meget almindelige (kan forekomme hos mere end 1 ud af 10 personer):</p>
<ul>
<li>usædvanlig træthed </li>
<li>smerter eller ømhed på injektionsstedet </li>
<li>kløe på injektionsstedet </li>
<li>muskelsmerter </li>
<li>hovedpine. </li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>diarré </li>
<li>kvalme eller opkastning </li>
<li>mavesmerter </li>
<li>rødme, blå mærker eller hævelse på indstiksstedet </li>
<li>udslæt </li>
<li>svimmelhed </li>
<li>ledsmerter </li>
<li>feber. </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer):</p>
<ul>
<li>hævede lymfeknuder </li>
<li>nældefeber eller kløende hud </li>
<li>rødme eller hedeture. </li>
</ul>
<p>Indberetning af bivirkninger 
Kontakt lægen eller apotekspersonalet eller sygeplejersken, hvis du får bivirkninger, herunder 
bivirkninger, som ikke er nævnt i denne indlægsseddel. Du kan også indberette bivirkninger direkte til 
Lægemiddelstyrelsen via det nationale indberetningssystem anført i Appendix V. Ved at indberette 
bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af denne vaccine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn. </p>
<p>Brug ikke vaccinen efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevar hætteglas i køleskab (2°C-8°C). Opbevares i den originale pakning for at beskytte mod lys. 
Må ikke nedfryses. </p>
<p>Smid ikke vacciner i afløbet. Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til 
lokale retningslinjer. Dette er med til at beskytte miljøet. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>PreHevbri indeholder: </p>
<p>En dosis (1 ml) indeholder:</p>
<ul>
<li>Aktive stoffer: 10 mikrogram hepatitis B-overfladeantigener (S [83 %], pre S2 [11 %] og 
pre S1 [6 %]) 1, 2 </li>
</ul>
<p>1 Adsorberet på 500 mikrogram Al3+ som aluminiumhydroxid, hydreret </p>
<p>2 Produceret i ovarieceller fra kinesiske hamstre ved hjælp af rekombinant DNA-teknologi </p>
<ul>
<li>Øvrige indholdsstoffer: natriumchlorid, kaliumchlorid, dinatriumphosphatdodecahydrat, 
kaliumdihydrogenphosphat, natriumhydroxid (til pH-justering), saltsyre (til pH-justering), vand 
til injektioner. </li>
</ul>
<p>Udseende og pakningsstørrelser 
PreHevbri er en klar, farveløs suspension med et fint hvidt bundfald. Når hætteglasset omrystes, bliver 
suspensionen let hvid og uigennemsigtig. </p>
<p>PreHevbri leveres i hætteglas, der indeholder 1 ml. Hætteglassene er kun til engangsbrug. </p>
<p>Pakninger med 1 eller 10 enkeltdosishætteglas er tilgængelige. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
VBI Vaccines B.V. 
Delflandlaan 1 
Queen's Tower, No. 1062EA Amsterdam 
Nederlandene </p>
<p>Fremstiller 
MIAS Pharma Limited 
Suite 1, First Floor, Stafford House 
Strand Road 
Portmarnock, D13 WCIrland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen </p>
<p>België/Belgique/Belgien 
Valneva France SAS 
France 
Tél/Tel: +43 120620 1e-mail: medinfo@valneva.com </p>
<p>Lietuva 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
България 
VBI Vaccines B.V. 
Netherlands 
Teл.: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Luxembourg/Luxemburg 
VBI Vaccines B.V. 
Netherlands 
Tél/Tel: +31 20 2997e-mail: medinfo@vbivaccines.com<br />
Česká republika 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Magyarország 
VBI Vaccines B.V. 
Netherlands 
Tel.: +31 20 2997e-mail: medinfo@vbivaccines.com 
Danmark 
Valneva Sweden AB 
Sweden 
Tlf: +43 120620 1e-mail: medinfo@valneva.com </p>
<p>Malta 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Deutschland 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Nederland 
Valneva France SAS 
France 
Tel: +43 120620 1e-mail: medinfo@valneva.com 
Eesti 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Norge 
Valneva Sweden AB 
Sweden 
Tlf: +43 120620 1e-mail: medinfo@valneva.com 
Ελλάδα 
VBI Vaccines B.V. 
Netherlands 
Τηλ: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Österreich 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
España 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Polska 
VBI Vaccines B.V. 
Netherlands 
Tel.: +31 20 2997e-mail: medinfo@vbivaccines.com 
France 
VBI Vaccines B.V. 
Netherlands 
Tél: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Portugal 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Hrvatska 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>România 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Ireland 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Slovenija 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
Ísland 
VBI Vaccines B.V. 
Netherlands 
Sími: +31 20 2997Netfang: medinfo@vbivaccines.com </p>
<p>Slovenská republika 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com<br />
Italia 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Suomi/Finland 
Valneva Sweden AB 
Sweden 
Puh/Tel: +43 120620 1e-mail: medinfo@valneva.com<br />
Κύπρος 
VBI Vaccines B.V. 
Netherlands 
Τηλ: +31 20 2997e-mail: medinfo@vbivaccines.com </p>
<p>Sverige 
Valneva Sweden AB 
Tel: +43 120620 1e-mail: medinfo@valneva.com 
Latvija 
VBI Vaccines B.V. 
Netherlands 
Tel: +31 20 2997e-mail: medinfo@vbivaccines.com 
United Kingdom (Northern Ireland) 
Valneva Austria GmbH 
Austria 
Tel: +43 120620 1e-mail: medinfo@valneva.com  </p>
<p>Denne indlægsseddel blev senest ændret i M.ÅÅÅÅ. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om denne vaccine på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Opbevaring 
- Hætteglassene bør opbevares i køleskab (2°C-8°C) ). De bør opbevares i den originale æske for 
at beskytte mod lys. 
- Må ikke nedfryses. </p>
<p>Forberedelse 
- Vaccinen bør anvendes under aseptiske forhold. 
- Suspensionen er svagt hvid og uigennemsigtig, når den blandes. Ved bundfældning er 
opløsningen klar og farveløs med hvidt bundfald. 
- Suspensionen bør kontrolleres visuelt inden administration. Hvis der observeres fremmede 
partikler og/eller variationer i den fysiske fremtoning, skal vaccinen kasseres. 
- Hætteglasset bør omrystes grundigt inden administration. </p>
<p>Administration 
- PreHevbri bør injiceres intramuskulært i deltamusklen. 
- Injicer ikke PreHevbri i glutealmusklen eller intradermalt eller intravaskulært. 
- Hætteglassene er kun til engangsbrug. 
- PreHevbri må ikke blandes med andre lægemidler. </p>
<p>Bortskaffelse 
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-6ad927719fc570edf8a72cacebe37a51
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for prehevbri Package Leaflet for language en"
Description: "ePI document Bundle for prehevbri Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6ad927719fc570edf8a72cacebe37a51"
* entry[0].resource = composition-en-6ad927719fc570edf8a72cacebe37a51

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6ad927719fc570edf8a72cacebe37a51"
* entry[=].resource = mp6ad927719fc570edf8a72cacebe37a51
                            
                    
Instance: bundlepackageleaflet-da-6ad927719fc570edf8a72cacebe37a51
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for prehevbri Package Leaflet for language da"
Description: "ePI document Bundle for prehevbri Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6ad927719fc570edf8a72cacebe37a51"
* entry[0].resource = composition-da-6ad927719fc570edf8a72cacebe37a51

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6ad927719fc570edf8a72cacebe37a51"
* entry[=].resource = mp6ad927719fc570edf8a72cacebe37a51
                            
                    



Instance: mp6ad927719fc570edf8a72cacebe37a51
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product PreHevbri 10 micrograms suspension for injection"
Description: "PreHevbri 10 micrograms suspension for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1641/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "PreHevbri 10 micrograms suspension for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6ad927719fc570edf8a72cacebe37a51ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "prehevbri"

* status = #current
* mode = #working

* title = "List of all ePIs associated with prehevbri"

* subject = Reference(mp6ad927719fc570edf8a72cacebe37a51)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#prehevbri "prehevbri"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6ad927719fc570edf8a72cacebe37a51) // prehevbri en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6ad927719fc570edf8a72cacebe37a51) // prehevbri da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6ad927719fc570edf8a72cacebe37a51
InstanceOf: List
Description: "ePI document List for prehevbri Package Leaflets"

* insert 6ad927719fc570edf8a72cacebe37a51ListRuleset
    